Contract Pharma Staff10.20.20
Mereo BioPharma Group plc, a clinical stage biopharmaceutical company focused on oncology and rare diseases, has appointed Christine Fox, CPA, as chief financial officer (CFO) and Heidi Petersen as senior vice president, regulatory affairs.
“Christine and Heidi are seasoned financial and regulatory executives and we are excited to welcome them to Mereo. The remainder of 2020 and 2021 will be an important period for Mereo as we expect multiple milestones across our pipeline, including the initiation of our Phase 1b/2 combination study with our anti-TIGIT antibody, etigilimab, in the coming weeks,” said Denise Scots-Knight, CEO of Mereo. “With the addition of Christine and Heidi, we believe we have an exceptional senior management team in place as we continue to execute on our clinical development and business objectives in preparation for our next stage of growth.”
Fox brings an extensive array of financial experience to Mereo, including a background in financial operations and reporting, technical accounting and external audit. She replaces Interim CFO and current Mereo Board member Michael Wyzga, who will continue to serve on Mereo’s Board.
Petersen brings more than 25 years of experience in the biopharmaceutical industry, with regulatory expertise across a range of therapeutic areas including immuno-oncology. Her appointment will be effective November 2, 2020 and Fox in January 2021.
“Christine and Heidi are seasoned financial and regulatory executives and we are excited to welcome them to Mereo. The remainder of 2020 and 2021 will be an important period for Mereo as we expect multiple milestones across our pipeline, including the initiation of our Phase 1b/2 combination study with our anti-TIGIT antibody, etigilimab, in the coming weeks,” said Denise Scots-Knight, CEO of Mereo. “With the addition of Christine and Heidi, we believe we have an exceptional senior management team in place as we continue to execute on our clinical development and business objectives in preparation for our next stage of growth.”
Fox brings an extensive array of financial experience to Mereo, including a background in financial operations and reporting, technical accounting and external audit. She replaces Interim CFO and current Mereo Board member Michael Wyzga, who will continue to serve on Mereo’s Board.
Petersen brings more than 25 years of experience in the biopharmaceutical industry, with regulatory expertise across a range of therapeutic areas including immuno-oncology. Her appointment will be effective November 2, 2020 and Fox in January 2021.
